Abstract
Background: In the recent years, the researches about HDAC inhibitors have become more and more extensive.
Objective: This study explored molecular docking mode and three-dimensional quantitative structureactivity relationship (3D-QSAR) of 18 novel HDAC inhibitors involving in quinolone structure.
Results: The molecular docking results showed that PHE198 might be a potential active residue against 18 HDAC inhibitors. 3D-QSAR model using Topomer CoMFA possessed high predictive ability (q2, 0.637; r2, 0.966).
Conclusion: Based on the results derived from molecular docking and 3D-QSAR studies, we designed several new compounds with potential inhibitory activity. We wish this study can provide some instructions for the design and structural transformation of novel potent quinolone-based HDAC inhibitors.
Keywords: HDAC inhibitor, quinolone-based, derivatives, 3D-QSAR, molecular docking, topomer CoMFA.
Letters in Drug Design & Discovery
Title:Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Volume: 13 Issue: 7
Author(s): Yi Bi, Zeyun Liu, Xianxuan Liu, Xiaochen Zhang and Jing Lu
Affiliation:
Keywords: HDAC inhibitor, quinolone-based, derivatives, 3D-QSAR, molecular docking, topomer CoMFA.
Abstract: Background: In the recent years, the researches about HDAC inhibitors have become more and more extensive.
Objective: This study explored molecular docking mode and three-dimensional quantitative structureactivity relationship (3D-QSAR) of 18 novel HDAC inhibitors involving in quinolone structure.
Results: The molecular docking results showed that PHE198 might be a potential active residue against 18 HDAC inhibitors. 3D-QSAR model using Topomer CoMFA possessed high predictive ability (q2, 0.637; r2, 0.966).
Conclusion: Based on the results derived from molecular docking and 3D-QSAR studies, we designed several new compounds with potential inhibitory activity. We wish this study can provide some instructions for the design and structural transformation of novel potent quinolone-based HDAC inhibitors.
Export Options
About this article
Cite this article as:
Bi Yi, Liu Zeyun, Liu Xianxuan, Zhang Xiaochen and Lu Jing, Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors, Letters in Drug Design & Discovery 2016; 13 (7) . https://dx.doi.org/10.2174/1570180812666150924000500
DOI https://dx.doi.org/10.2174/1570180812666150924000500 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma
Current Stem Cell Research & Therapy LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Nanoparticles and Associated Toxicity
Current Nanoscience Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry HCV-Related Central and Peripheral Nervous System Demyelinating Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy
Current Molecular Medicine Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Synthetic and Biological Attributes of Pyrimidine Derivatives: A Recent Update
Current Organic Synthesis Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets